Latest news with #Synthego
Time Business News
6 days ago
- Business
- Time Business News
iPSC Demand Rises with Cancer Research and Regenerative Therapies
Induced Pluripotent Stem Cells (iPSC) come from blood and skin cells. These cells are changed back to an embryonic-like state. This allows for a limitless amount of any human cell type needed for different therapeutic uses. The rise in cancer cases and research into Induced Pluripotent Stem Cells are key drivers of market expansion. The increasing involvement of major companies and research institutions in exploring stem cell-based treatments supports this expansion. The wide variety of uses, such as in regenerative medicine, drug creation, tissue engineering, toxicity testing, and cell therapies, should increase the need for Induced Pluripotent Stem Cells in the coming years. Key Growth Drivers and Opportunities Increasing Chronic Cases: Increasing prevalence of diseases and demand for therapies has become a leading factor in market growth. As induced potential stem cells comes from patients own cells it offers great therapeutic potential which in turn boost the demand for IPSC growth. Use of induced pluripotent stem cell in therapies has driven the demand in market. Challenges Expensive treatments and a lack of awareness about stem cell therapies have slowed the growth of Induced Pluripotent Stem Cells. Limited reimbursement policies in many regions keep patients from choosing these advanced therapies. Ethical concerns and regulations continue to slow clinical adoption. The technology of iPSC generation and differentiation is another challenge for broad use. These things together limit the market's full potential, despite the therapeutic benefits. Innovation and Expansion Applied StemCell and CIRM Partner to Advance Clinical-Grade iPSC Therapies In June 2023, Applied StemCell Inc., partnered with CIRM (California Institute for Regenerative Medicine) to offer clinical-grade induced pluripotent stem cells with MCB (master cell bank) and WCB (working cell bank) and to access its proprietary gene editing technologies for accelerating the development of advanced regenerative therapies. This partnership seeks to aid the making of standard, top-notch cell lines for use in clinical settings. It also improves how well and safely iPSC-created treatments can be used. By joining expert knowledge, this teamwork should boost new ideas in gene-edited treatments that help the body heal itself from hard-to-treat illnesses. Synthego Unveils Scalable iPSC Genome Engineering Platform In October 2022, Synthego launched high throughput genome engineering for induced pluripotent stem cells. The new launched tool will expand the Synthego's efficiency of induced pluripotent cells at an industrial scale. Synthego has introduced high-throughput genome engineering for induced pluripotent stem cells. The new tool will broaden Synthego's competence with induced pluripotent cells on a large scale. This development helps with precise and scalable gene editing, speeding up the progress of stem cell-based treatments. It also lowers the amount of manual work needed, which improves how well research is repeated and how much work can be done. It is anticipated that the platform will promote drug discovery, disease modeling, and advances in regenerative medicine. Inventive Sparks, Expanding Markets The key players operating the induced pluripotent stem cells market includes, Lonza, Evotec SE, Thermo Fisher Scientific Inc., Axol Bioscience Ltd., among others. Companies are working together to speed up stem cell therapy creation through better genome engineering that can be expanded. Their main goals are to lower expenses, make results more consistent, and process more data for both study and treatment uses. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Associated Press
12-06-2025
- Business
- Associated Press
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
REDWOOD CITY, Calif., June 12, 2025 /PRNewswire/ -- Synthego, a pioneering CRISPR Solutions provider, is pleased to announce that the US Court of Appeals for the Federal Circuit has upheld an earlier ruling invalidating patents held by Agilent Technologies, Inc. See the ruling here. In the original case, ruling dated May 17, 2023, the Patent Trial and Appeal Board (PTAB) ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos. 10,337,001 (the '001 patent) and 10,900,034 (the '034 patent) in the Inter Partes Review before the PTAB. The PTAB's original decision invalidated all claims of the Agilent patents, which were directed to guide RNAs having at least one 2'-O-methyl modification ('034 patent) and guide RNAs having certain modifications within 5 nucleotides of their 5' and/or 3' end ('001) patent), as well as methods of using such modified guide RNAs for CRISPR gene editing. 'This critical decision, affirming that Agilent's claims on chemically modified gRNAs are unpatentable, keeps the path clear for broader innovation and advancement in the CRISPR therapeutics market,' said Craig Christianson, CEO of Synthego. 'Synthego will continue our focus on supporting our clients' efforts to enhance human health with curative cell and gene therapies.' Synthego continues to support innovation in the field of CRISPR-enabled research and therapeutics, this affirmation enables researchers and therapeutic developers to continue to drive successful patient outcomes. About Synthego Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. View original content to download multimedia: SOURCE Synthego
Bloomberg
06-05-2025
- Business
- Bloomberg
Gene-Editor Synthego Files Bankruptcy With Plans to Sell Itself to Lenders
Synthego Corp., which makes gene-editing tools for drug developers and other researchers, filed for bankruptcy with plans to sell itself to its main lender, an affiliate of private equity firm Perceptive Advisors. Perceptive Credit Holdings III would trade as much as $85 million in debt for ownership of Synthego, unless a higher offer comes in, the company said in a proposal filed Monday in federal court in Wilmington, Delaware. Perceptive manages about $8 billion that is largely focused on health-care technology.
